

EUROPEAN
CURRICULUM VITAE
FORMAT



PERSONAL INFORMATION

Name **SEGUELLA LUISA**
Address
Telephone
E-mail

Nationality Italian
Date of Birth

Gender Female

WORK EXPERIENCE

- From March 2021 to current **RESEARCH ASSOCIATE (POSTDOC)**
Michigan State University, East Lansing (MI), USA
Department of Physiology
Enteric Neuroscience and Gastrointestinal Pharmacology
Research projects performer and designer
- From Nov 2020 to March 2021 **GRADUATE STUDENT**
Michigan State University, East Lansing (MI), USA
Department of Physiology
Enteric Neuroscience and Gastrointestinal Pharmacology
Research projects performer and designer
- From Sept 2018 to Nov 2020 **Ph.D. VISITING SCHOLAR**
Michigan State University, East Lansing (MI), USA
Department of Physiology
Enteric Neuroscience and Gastrointestinal Pharmacology
Ph.D. research project performer and designer
- From Feb 2017 to Marzo 2017 **PREDOC FELLOWSHIP (INCARICO PER PRESTAZIONE OCCASIONALE)**
Sapienza University of Rome, Italy
Department of Drug Chemistry and Technology
Gastrointestinal Pharmacology and Toxicology
Research project in "In vitro and in vivo characterization of antimicrobial drugs nano-vesicular transport systems able to modulate inflammatory processes at the basis of Parkinson's disease", funding by Sapienza University of Rome. Research projects performer and designer.
- June 2016 **PREDOC FELLOWSHIP (INCARICO PER PRESTAZIONE OCCASIONALE)**
University of Naples "Federico II", Italy
Department of Clinical Medicine and Surgery
Gastrointestinal Pharmacology and Toxicology
Research projects in "Modulation of intestinal permeability in Parkinson's disease - data collection for the study of pharmacological effects and possible alternative

therapeutic replacement of rifamicine antibiotic's family ", funded by Alfa Wassermann. Research projects performer and designer.

TEACHING EXPERIENCE

From March 2021 to current

EXPERT IN PHARMACOLOGY AND TOXICOLOGY (CULTORE DELLA MATERIA IN FARMACOLOGIA E TOSSICOLOGIA)

Sapienza University of Rome, Italy
Department of Physiology and Pharmacology "V. Erspamer"
Gastrointestinal Pharmacology and Toxicology
Examination committee member for the courses: "Farmacologia Speciale e Farmacoterapia (M-Z)" and "Farmacoepidemiologia e Farmacovigilanza".

EDUCATION AND TRAINING

From Nov 2017 to Dec 2020

Ph.D. IN PHARMACOLOGY AND TOXICOLOGY

Excellent "**Summa Cum laude**"

Three-years doctoral fellowship
Sapienza University of Rome, Italy
Department of Physiology and Pharmacology "V. Erspamer"
Ph.D. research project in "Enteric glia: a heterogeneous population of peripheral neuroglia that link the "gut wellness to brain wellness"
Ph.D. research project performer and designer

From Sept 2018 to Nov 2020

Ph.D. VISITING SCHOLAR

Michigan State University, East Lansing (MI), USA
Department of Physiology
Enteric Neuroscience and Gastrointestinal Pharmacology
Ph.D. research project performer and designer

Dec 2016

PHARMACIST LICENSURE EXAMINATION 350/350

Sapienza University of Rome, Italy
Department of Drug Chemistry and Technology

Jan 2016

MD IN PHARMACEUTICAL CHEMISTRY 110/110 cum laude

Sapienza University of Rome, Italy
Department of Physiology and Pharmacology "V. Erspamer"
Gastrointestinal Pharmacology and Toxicology
MD research project in "Rifaximin, a non-absorbable antibiotic, inhibits the release of pro-angiogenic mediators in colon cancer cells through a pregnane X receptor-dependent pathway".
MD research project performer and designer

GRANTS AND AWARDS

Sept 2021

FARMINDUSTRIA 2021 AWARD

Prize to the best research activity in pharmacology in the 2021
Supported by Italian Pharmacology Society (SIF) and Farmindustria

Sept 2020

SAPIENZA STARTING GRANT 2020 (BANDI DI ATENE SAPIENZA "AVVIO ALLA RICERCA" 2020)

"Make your intestine an own-made drug factory: genetically modified *Lactobacillus paracasei* producing palmitoylethanolamide (PEA) heals colitis in mice (AR12017286C7F7A1).
Supported by Sapienza University of Rome.
Principal investigator.

March 2020

FNM 2020 YOUNG INVESTIGATOR AWARD

Travel grant to the early career researchers in Neurogastroenterology and Motility.
Supported by European Society of Neurogastroenterology and Motility (ESNM)

- Sept 2019 **SAPIENZA STARTING GRANT 2019 (BANDI DI ATENE SAPIENZA "AVVIO ALLA RICERCA" 2019)**
"Cholecystokinin: a gut-brain peptide that links enteric glial-mediated neuroinflammation to the development of neurobehavioral disorders in HFD-induced leaky gut" (AR11916B5258C170).
Supported by Sapienza University of Rome.
Principal investigator.
- April 2019 **PARKINSON'S AND MOVEMENT DISORDERS FOUNDATION (PMDF) GRANT**
"Innovative Parkinson's disease modifying strategy: preclinical evaluation of intranasal delivery of pentamidine (IN-pentasome) in MPTP-intoxicated mice" (PMDF grant winners 2019 - https://www.pmdf.org/articles/2019-Grant_recipients_ESPOSITO_09APR2019.php)
Collaborator.
- Jan 2019 **YOUNG RESEARCHER AWARD**
Prize to the best young researcher in the Dept. of Physiology and Pharmacology "V. Erspamer" in the 2019.
"inPentasomes: An innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice
Supported by Dept. of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome.
- Sept 2018 **SAPIENZA STARTING GRANT 2018 (BANDI DI ATENE SAPIENZA "AVVIO ALLA RICERCA" 2018)**
"High fat diet and depressive-like behavior in mice: the role of entia glia as missing link between metabolic and neuropsychiatric disorders" (AR11816433B8F7F8).
Supported by Sapienza University of Rome.
Principal investigator.
- Oct 2018 **SIF ABROAD FELLOWSHIP**
"High fat diet and depressive-like behavior in mice: the role of entia glia as missing link between metabolic and neuropsychiatric disorders".
Supported by Italian Pharmacology Society (SIF)
SIF Abroad Fellowships providing opportunities for Ph.D. students to undertake study, research, or professional development overseas.

RESEARCH ACTIVITY

My research interests mainly focus on gastrointestinal pharmacology, the cellular mechanisms of gastrointestinal disorders, and their related consequences on the gut-brain axis. Within this context, I am targeting my research on generating lab-engineered probiotics for on-demand production of bioactive autacoid local injury antagonist amides (ALIAmides) and cannabinoids, and their possible application in the treatment and prevention of gut inflammatory conditions, dysbiosis, and neuropsychiatric disorders.

In the last years, I was also involved in discovering new druggable targets for the treatment of these pathological conditions and I focused on enteric glia. In particular, I am studying how enteric glia, a unique population of peripheral neuroglia in the enteric nervous system (ENS), interact with the surrounding neurons, immune cells, and intestinal microbiota to influence intestinal and brain functions in health and disease.

Working in different labs also provided me with a dynamic and multidisciplinary network of collaborations that are a central part of my research activity. These include the lab of Dr. Brian Gulbransen lab at Michigan State University (East Lansing, USA), Dr. Giovanni Sarnelli at the University of Naples "Federico II" (Naples), Dr. Carla Cirillo at INSERM (Toulouse Neuroimaging Center, France), and Dr. Jie Lu at China Medical University (Shenyang City, China).

EDITORIAL EXPERIENCES

- From 2021 **REVIEWER EDITOR**
Frontiers in Neuroscience
- 2020 **Ad-doc REVIEWER FOR**
Frontiers Cell and Developmental Biology
PLOS ONE
Neuropharmacology
- 2020 **GUEST CO-EDITOR**
Research Topic "Nutraceuticals: Novel Insights for a Natural Approach for Leaky Gut Syndrome" for Frontiers in Pharmacology
Special Issue "The Effect of Probiotics on Gut Homeostasis Regulation" for International Journal of Molecular Sciences
- From 2019 **REVIEWER EDITOR**
Frontiers in Pharmacology – Ethnopharmacology
- REVIEWER EDITOR**
Gastroenterology and Hepatology research
- 2019 **Ad-doc REVIEWER FOR**
Journal of Medical Food

MEMBERSHIP IN PROFESSIONAL ASSOCIATIONS

- 2021 American Neurogastroenterology and Motility Society (ANMS)
- 2020 Society of Neuroscience (SfN)
- 2019 European Society of Neurogastroenterology and Motility (ESNM)
Michigan Physiology Society (MPS)
- 2018 Federation of European Neuroscience Societies (FENS)
Italian Society for Neuroscience (SINS)
- 2016 Italian Pharmacology Society (SIF)

CONFERENCE SPEAKER AND CHAIR

- Oct 11, 2021 **CONFERENCE SPEAKER**
Gastrointestinal Group Meeting
"Functional And Regional Heterogeneity Of Glial Cells In The Enteric Nervous System". Department of Physiology, Michigan State University, East Lansing (MI), USA.
- Aug 13-15,2021 **CONFERENCE SPEAKER**
2021 American Neurogastroenterology and Motility (ANMS) Annual Meeting
"Functional and regional heterogeneity of glial cells in the enteric nervous system". Westin Boston Seaport District Boston, Massachusetts.
- April 1st, 2021 **CHAIRPERSON**
PSL John F. Sander and Nancy K. Dunkel Webinar Presentation – MSU Spring Semester 2021
"Enteric nervous system and glucose metabolism: determine the impact of the gut-brain axis on glucose metabolism". Department of Physiology, Michigan State University, East Lansing (MI), USA.
- March 10-13, 2021 **INVITED CONFERENCE SPEAKER**

40th National Conference of Italian Pharmacology Society (SIF)
"Role of enteric glia as bridging element between acute gut inflammation and chronic visceral pain".
SIF week Digital Edition.

March 8, 2021

CONFERENCE SPEAKER

40th National Conference of Italian Pharmacology Society (SIF) - XXIII SIF Seminar on Pharmacology for Ph.D. Students, Fellows, Post Doc, and Specialist Trainees.

"Enteric glia activation is associated with a decrease in neurogenesis and neuronal dendritic spines both in the enteric and central nervous systems, and depressive and anxiety-like behaviors in HFD mice". SIF week Digital Edition.

CONFERENCE POSTER

"Functional and regional heterogeneity of glial cells in the enteric nervous system".

Seguella L, Esposito G, Gulbransen BD. 4th Meeting of the Federation of Neurogastroenterology and Motility, Virtual Edition, April 14-17, 2021.

"Enteric glia activation by HIV-1 Tat-induced diarrhea drives a glial inflammatory reaction to the central nervous system associated with a significant cognitive decline".

Seguella L, Pesce M, Capuano R, Sarnelli G, Pesce M and Esposito G.

39th National Conference of Italian Pharmacology Society (SIF), Florence, November 20-23, 2019, Italy.

"Regional heterogeneity of cholecystokinin sensing by enteric glia"

Seguella L, Esposito G, Gulbransen BD. 12th Great Lakes Glia Meeting 2019. Traverse City (MI), Sept 29-Oct 1st, 2019, USA.

"Regional heterogeneity of cholecystokinin sensing by enteric glia"

Seguella L, Esposito G, Gulbransen BD. XIV European Meeting on Glial cells in Health and Disease, Porto, July 10-13, 2019, Portugal.

"Regional heterogeneity of cholecystokinin sensing by enteric glia"

Seguella L, Esposito G, Gulbransen BD. 2019 Michigan Physiology Society (MPS) Meeting. Central Michigan University, Mount Pleasant (MI), June 27, 2019, USA.

"Regional heterogeneity of cholecystokinin sensing by enteric glia"

Seguella L, Esposito G, Gulbransen BD. 2019 MSU Physiology Department retreat meeting. Michigan State University, East Lansing (MI), May 10, 2019, USA.

"Rifaximin, a non-absorbable antibiotic, inhibits the release of pro-angiogenic mediators in colon cancer cells through a pregnane X receptor-dependent pathway"

Seguella L, Gigli S, Pesce M, Steardo L, Sarnelli G, Esposito G.. 38th National Conference of Pharmacology Italian Society (SIF), Rimini, October 25-28, 2017, Italy.

"Targeting S100B-p53wt protein-protein interaction with Pentamidine: a novel approach to contrast chronic inflammation-induced colon cancer drift"

Gigli S, **Seguella L**, Pesce M, Sterado L, Sarnelli G, Esposito G.. 38th National Conference of Pharmacology Italian Society (SIF), Rimini, October 25-28, 2017, Italy.

"Inhibition of S100B-p53wt interaction by pentamidine counteracts carcinogenic drift in human colon cancer"

Gigli S, **Seguella L**, Pesce M, Sterado L, Sarnelli G, Esposito G.. 22nd World congress on advances in oncology Athens, 5-7 october 2017

Gigli S, **Seguella L**, Nobile N, Pesce M, D'Alessandro A, Steardo L, Sarnelli G, Esposito G. Cannabidiol attenuates Clostridium difficile Toxin A (TcdA) damage in human Colon Carcinoma Caco-2 cell line. 26th Annual ICRS Symposium on the Cannabinoids, Bukovina, June 26- July 1st, 2017 Poland.

SUMMARY OF SCIENTIFIC ACHIEVEMENTS

Total Impact Factor (JCI)	202.503 (mean IF:7.788)
Total Citation (Scopus)	298
Hirsch (H) Index (Scopus)	11
Documents by Author	26

LIST OF PUBLICATION

1. Corpetti C, Del Re A, **Seguella L**, Palenca I, Rurgo S, De Conno B, Pesce M, Sarnelli G, Esposito G*. Cannabidiol inhibits SARS-Cov-2 spike (S) protein-induced cytotoxicity and inflammation through a PPAR γ -dependent TLR4/NLRP3/Caspase-1 signaling suppression in Caco-2 cell line. *Phytother Res.* 2021 Oct 12. doi: 10.1002/ptr.7302. Online ahead of print. **IF (2020): 5.878 Citations: (Scopus)**
2. Ahmadzai MM, **Seguella L**, Gulbransen BD*. Circuit-specific enteric glia regulate intestinal motor neurocircuits. *Proc Natl Acad Sci U S A.* 2021 Oct 5;118(40):e2025938118. doi:10.1073/pnas.2025938118. Epub 2021 Sep 30. **IF (2020): 11.205 Citations: (Scopus)**
3. Del Re A, Corpetti C, Pesce M, **Seguella L**, Steardo L, Palenca I, Rurgo S, De Conno B, Sarnelli G, Esposito G*. Ultramicrosized palmitoylethanolamide inhibits NLRP3 inflammasome expression and pro-inflammatory response activated by SARS-CoV-2 spike protein in cultured murine alveolar macrophages. *Metabolites.* 2021 Sep 2;11(9):592. doi: 10.3390/metabo11090592. **IF (2020):4.932 Citations: (Scopus)**
4. **Seguella L**, Gulbransen BD*. Enteric glial biology, intercellular signalling and roles in gastrointestinal disease. *Nat Rev Gastroenterol Hepatol.* 2021 Aug;18(8):571-587. doi: 10.1038/s41575-021-00423-7. Epub 2021 Mar 17. **IF (2020): 46.802 Citations: 3 (Scopus)**
5. **Seguella L**, Pesce M, Capuano R, Casano F, Pesce M, Corpetti C, Vincenzi M, Maffei D, Lattanzi R, Del Re A, Sarnelli G, Gulbransen BD, Esposito G*. High-fat diet impairs duodenal barrier function and elicits glia-dependent changes along the gut-brain axis that are required for anxiogenic and depressive-like behaviors. *J Neuroinflammation.* 2021 May 16;18(1):115. doi: 10.1186/s12974-021-02164-5. **IF (2020):8.322 Citations: (Scopus)**
6. Esposito G, Corpetti C, Pesce M, **Seguella L**, Annunziata G, Del Re A, Vincenzi M, Lattanzi R, Lu J, Sanseverino W, Sarnelli G*. A palmitoylethanolamide producing *Lactobacillus paracasei* improves Clostridium difficile toxin A-induced colitis. *Front Pharmacol.* 2021 Apr 27; 12:639728. doi: 10.3389/fphar.2021.639728. eCollection 2021. **IF (2020): 5.810 Citations: (Scopus)**
7. Esposito G, Pesce M, **Seguella L**, Lu J, Corpetti C, Del Re A, De Palma FDE, Esposito G, Sanseverino W, Sarnelli G*. Engineered *Lactobacillus paracasei* producing palmitoylethanolamide (PEA) prevents colitis in mice. *Int J Mol Sci.* 2021 Mar 14;22(6):2945. doi: 10.3390/ijms22062945. **IF (2020): 5.923 Citations: 1 (Scopus)**
8. Pesce M, **Seguella L**, Cassarano S, Aurino L, Sanseverino W, Lu J, Corpetti C, Del Re A, Vincenzi M, Sarnelli G, Esposito G*. Phytotherapeutics in COVID19: Why palmitoylethanolamide? *Phytother Res.* 2020 Dec 9. doi: 10.1002/ptr.6978. Online ahead of print. **IF (2020): 5.878 Citations: 5 (Scopus)**
9. Esposito G, Pesce M, **Seguella L**, Sanseverino W, Lu J, Corpetti C, Sarnelli G*. The potential of cannabidiol in the COVID-19 pandemic. *Br J Pharmacol.* 2020 Nov;177(21):4967-4970. doi: 10.1111/bph.15157. Epub 2020 Jul 16. **IF (2020): 8.739 Citations: 24 (Scopus)**
10. Sarnelli G, Pesce M, **Seguella L**, Lu J, Efficie E, Tack J, Elisa De Palma FD, D'Alessandro A, Esposito G*. Impaired duodenal palmitoylethanolamide release underlies acid-induced mast cell activation in functional dyspepsia. *Cell Mol Gastroenterol Hepatol.* 2021;11(3):841-855. doi: 10.1016/j.jcmgh.2020.10.001. Epub 2020 Oct 14. **IF (2020): 9.225 Citations: 1 (Scopus)**
11. Pietrangeli P, Corpetti C, **Seguella L***, DI Re A, Pesce M, Vincenzi M, Lori C, Annunziata G, Mateescu MA, Sarnelli G, Esposito G*, Marcocci L. Lathyrus sativa diamine oxidase reduces Clostridium difficile toxin A-induced toxicity in Caco-2 cells by rescuing RhoA-GTPase and inhibiting pp38-MAPK/NF- κ B/HIF1 α activation. *Phytotherapy Research.* 2021 Jan;35(1):415-423. doi: 10.1002/ptr.6814. Epub 2020 Sep 10. **IF (2020): 5.878 Citations: (Scopus)**
12. Esposito G, Pesce M, **Seguella L**, Sanseverino W, Lu J, Sarnelli G*. Can the enteric nervous system be an alternative entrance door in SARS-CoV2 neuroinvasion?. *Brain Behav Immun.*

2020;87:93-94. doi:10.1016/j.bb.2020.04.060. Epub 2020 Apr 23. **IF (2020): 7.217 Citations: 25 (Scopus)**

13. **Seguella L**, Rinaldi F, Marianecchi C, Capuano R, Pesce M, Annunziata G, Casano F, Bassatti G, Sidoni A, Milone M, Aprea G, De Palma GD, Carafa M, Pesce M, Esposito G, Sarnelli G*. Pentamidine niosomes thwart S100B effects in human colon carcinoma biopsies favouring wtp53 rescue. 2020 Mar; 24(5):3053-3063. doi: 10.1111/jcmm.14943. Epub 2020 Feb 5. **IF (2020): 5.310 Citations: 7 (Scopus)**

14. **Seguella L**, Sarnelli G, Esposito G*. Leaky gut, dysbiosis, and enteric glia activation: the trilogy behind the intestinal origin of Parkinson's disease. *Neural Regen Res*. 2020 Jun;15(6):1037-1038. doi: 10.4103/1673-5374.270308. **IF (2020): 5.135 Citations: 7 (Scopus)**

15. **Seguella L**, Capuano R, Pesce M, Annunziata G, Pesce M, de Conno B, Sarnelli G, Aurino L, Esposito G. S100B protein stimulates proliferation and angiogenic mediators release through RAGE/pAkt/mTOR pathway in human colon adenocarcinoma Caco-2 cells. *Int J Mol Sci*. 2019 Jul 1;20(13):3240. doi: 10.3390/ijms20133240. **IF (2020): 5.293 Citations: 17 (Scopus)**

16. Pietrangeli P, **Seguella L**, Annunziata G, Casano F, Capuano R, Pesce M, De Conno B, Gigli S, Sarnelli G, Pesce M, Mateescu MA, Esposito G, Marcocci L. Lathyrus sativus diamine oxidase counteracts histamine-induced cell proliferation, migration and pro-angiogenic mediators release in human colon adenocarcinoma cell line Caco-2. *Phytother Res*. 2019 Jul;33(7):1878-1887. doi: 10.1002/ptr.6378. Epub 2019 May 29. **IF (2020): 5.878 Citations: 5 (Scopus)**

17. **Seguella L**, Capuano R, Sarnelli G, Esposito G. Play in advance against neurodegeneration: exploring enteric glial cells in gut-brain axis during neurodegenerative diseases. *Expert Rev Clin Pharmacol*. 2019 Jun;12(6):555-564. doi: 10.1080/17512433.2019.1612744. Epub 2019 May 6. **IF (2020): 3.481 Citations: 6 (Scopus)**

18. Rinaldi F, 1, **Seguella L**, 1, Gigli S, 1, Hanieh P N, Del Favero E, Cantù L, Pesce M, Sarnelli G, Marianecchi C, Esposito G, Carafa M*. inPentosomes: An innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice. *J Control Release*. 2019 Jan 28;294:17-26. doi: 10.1016/j.jconrel.2018.12.007. Epub 2018 Dec 7. **IF (2020): 9.776 Citations: 15 (Scopus)**

19. Sarnelli G, **Seguella L**, Pesce M, Lu J, Gigli S, Bruzzese E, Lattanzi R, D'Alessandro A, Cuomo R, Steardo L, Esposito G*. HIV-1 Tat-induced diarrhea is improved by the PPAR alpha agonist, palmitoylethanolamide, by suppressing the activation of enteric glia. *J Neuroinflammation*. 2018 Mar 24;15(1):94. doi: 10.1186/s12974-018-1126-4. **IF (2020):8.322 Citations: 9 (Scopus)**

20. Pesce M, D'Alessandro A, Borrelli O, Gigli S, **Seguella L**, Cuomo R, Esposito G, Sarnelli G*. Endocannabinoid-related compounds in gastrointestinal diseases. *J Cell Mol Med*. 2018 Feb;22(2):706-715. doi: 10.1111/jcmm.13359. Epub 2017 Oct 9. **IF (2020): 5.310 Citations: 25 (Scopus)**

21. Esposito G, Capoccia E, Gigli S, Pesce M, Bruzzese E, D'Alessandro A, Cirillo C, di Cerbo A, Cuomo R, **Seguella L**, Steardo L, Sarnelli G*. HIV-1 Tat-induced diarrhea evokes an enteric glia-Dependent neuroinflammatory response in the central nervous system. *Sci Rep*. 2017 Aug 10;7(1):7735. doi: 10.1038/s41598-017-05245-9. **IF (2020): 4.379 Citations: 43 (Scopus)**

22. Gigli S, **Seguella L**, Pesce M, Bruzzese E, D'Alessandro A, Cuomo R, Steardo L, Sarnelli G, Esposito G*. Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by Clostridium difficile toxin A in Caco-2 cells. *United European Gastroenterol J*. 2017 Dec;5(8):1108-1115. doi: 10.1177/2050640617698622. Epub 2017 Mar 13. **IF (2020): 4.623 Citations: 14 (Scopus)**

23. Esposito G, Gigli S, **Seguella L**, Nobile N, D'Alessandro A, Pesce M, Capoccia E, Steardo L, Cirillo C, Cuomo R, Sarnelli G*. Rifaximine, a non-absorbable antibiotic, inhibits the release of pro-angiogenic mediators in colon cancer cells through a pregnane X receptor-dependent pathway. *Int J Oncol*. 2016 Aug;49(2):639-45. doi: 10.3892/ijo.2016.3550. Epub 2016 Jun 1. **IF (2020): 3.899 Citations: 14 (Scopus)**

24. Esposito G, Nobile N, Gigli S, **Seguella L**, Pesce M, d'Alessandro A, Bruzzese E, Capoccia E, Steardo L, Cuomo R, Sarnelli G*. Rifaximine improves Clostridium difficile Toxin A-induced toxicity in Caco-2 cells by the PXR-dependent TLR4/MyD88/Nf-kB pathway. *Front Pharmacol*. 2016 May

25. Sarnelli G, D'Alessandro A, Iuvone T, Capoccia E, Gigli S, Pesce M, **Seguella L**, Nobile N, Aprea G, Maione F, de Palma GD, Cuomo R, Steardo L, Esposito G*. Palmitoylethanolamide modulates inflammation-associated Vascular Endothelial Growth Factor (VEGF) signaling via the Akt/mTOR pathway in a selective Peroxisome Proliferator-Activated Receptor Alpha (PPAR- α)-dependent manner. PLoS One. 2016 May 24;11(5):e0156198. doi: 10.1371/journal.pone.0156198. eCollection 2016. **IF (2020): 3.240 Citations: 25 (Scopus)**

26. Sarnelli G, Gigli S, Capoccia E, Iuvone T, Cirillo C, **Seguella L**, Nobile N, D'Alessandro A, Pesce M, Steardo L, Cuomo R, Esposito G*. Palmitoylethanolamide exerts antiproliferative effect and downregulates VEGF signaling in Caco-2 Human Colon Carcinoma Cell line through a selective PPAR- α -dependent inhibition of Akt/mTOR pathway. Phytother Res. 2016 Jun;30(6):963-70. doi: 10.1002/ptr.5601. Epub 2016 Mar 1. **IF (2020): 5.878 Citations: 17 (Scopus)**

PERSONAL SKILLS AND COMPETENCES

MADRELINGUA

ITALIAN

ALTRE LINGUA

ENGLISH

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

EXCELLENT

EXCELLENT

EXCELLENT

SOCIAL SKILLS AND COMPETENCES

Living and working abroad, in multicultural environments, in positions where communication is important and situations where teamwork is essential, made me flexible and adaptable to each kind of situations. I developed a wide spectrum of view regarding the diverse situation and a quick problem solving that I apply to the diverse aspects of working in team.

ORGANISATIONAL SKILLS AND COMPETENCES

Working in different labs improved my coordination and administration skills, and handle the leadership of projects and budgets made me able to organize efficiently my own work and coordinate people simultaneously on other projects. I am able to plan how to reach my goals and understand which aspects require improvement or changes.

TECHNICAL SKILLS AND COMPETENCES

Generation of genetically modified strains of probiotics (modification and insertion of selected genes in plasmid vectors, development, and transfection of bacteria strains by plasmid constructs)

Bacteria and Cell cultures (cell isolation, cell culture, pharmacological manipulation, images acquisition)

A diverse array of techniques to investigate pathological conditions affecting the nervous system with particular regarding the enteric nervous system (calcium imaging with genetically encoded indicators, chemogenetics, optogenetics, genomics, intestinal disease models, and in vivo and in vitro physiological assays).

Microscopy array of techniques (immunofluorescence, immunohistochemistry, and histological staining, organs and tissues isolation, images acquisition, histomorphometric quantification by microscopic image software)


DRIVING LICENCE(S)

B Driver's Licence

Date and place:

21 DICEMBRE 2021.

Signature



Luisa Seguella